Patents by Inventor Aya Jakobovits

Aya Jakobovits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF INDUCING AN IMMUNE RESPONSE
    Publication number: 20110150910
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: January 13, 2010
    Publication date: June 23, 2011
    Applicant: Agensys, Inc.
    Inventors: Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
  • Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer
    Patent number: 7960527
    Abstract: A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: June 14, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Methods of inducing an immune response
    Patent number: 7951375
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: May 31, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 151P3D4 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20110123539
    Abstract: A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Applicant: AGENSYS, INC.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 7947276
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: May 24, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7947459
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high'degree of structural conservation among them but show no significant structural homology to any known human proteins. STEAP-2 is a 454 amino acid protein characterized by a predicted molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: January 6, 2004
    Date of Patent: May 24, 2011
    Assignee: Agensys, Inc.
    Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20110110952
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Application
    Filed: January 5, 2011
    Publication date: May 12, 2011
    Applicant: AGENSYS, INC.
    Inventors: Pia M. CHALLITA-EID, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
    Patent number: 7939503
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: May 10, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
    Patent number: 7935491
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: May 3, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
  • Methods to inhibit cell growth
    Patent number: 7927597
    Abstract: A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Wangmao Ge, Juan J. Perez-Villar, Steven B. Kanner, Aya Jakobovits
  • Gene upregulated in cancers of the prostate
    Patent number: 7928212
    Abstract: The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Arthur B. Raitano, Rene S. Hubert, Steve Chappell Mitchell, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
    Patent number: 7928196
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
  • METHODS TO INHIBIT CELL GROWTH
    Publication number: 20110086437
    Abstract: A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization.
    Type: Application
    Filed: October 28, 2010
    Publication date: April 14, 2011
    Inventors: Arthur B. RAITANO, Pia M. CHALLITA-EID, Wangmao GE, Juan J. PEREZ-VILLAR, Steven B. KANNER, Aya JAKOBOVITS
  • Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer
    Patent number: 7923543
    Abstract: A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 12, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 158P3D2 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20110082095
    Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.
    Type: Application
    Filed: October 6, 2010
    Publication date: April 7, 2011
    Applicant: AGENSYS, INC.
    Inventors: ARTHUR B. RAITANO, AYA JAKOBOVITS, PIA M. CHALLITA-EID, STEVEN B. KANNER, WANGMAO GE, JUAN J. PEREZ-VILLAR, ROBERT KENDALL MORRISON
  • Secreted protein called 36P6D5 characteristic of tumors
    Patent number: 7897740
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary, and pancreas.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: March 1, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Aya Jakobovits, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
  • 121P1F1: a tissue specific protein highly expressed in various cancers
    Patent number: 7892548
    Abstract: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: February 22, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Rene S. Hubert, Steven Chappell Mitchell, Arthur B. Raitano, Mary Faris, Daniel E. H. Afar, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
    Patent number: 7884179
    Abstract: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: February 8, 2011
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Wangmao Ge, Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
    Patent number: 7879570
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: February 1, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20110020353
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: September 14, 2010
    Publication date: January 27, 2011
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-Chi Jia, Jean Gudas